24/7 Market News Snapshot 23 January, 2025 – Tiziana Life Sciences Ltd. Common Shares (NASDAQ:TLSA)
DENVER, Colo., 23 January, 2025 (247marketnews.com) – (NASDAQ:TLSA) are discussed in this article.
Tiziana Life Sciences Ltd. (TLSA) opened today at $0.80 and has shown a noteworthy upward trajectory, currently trading at $0.818, reflecting an increase of approximately 2.65% from the previous session’s close of $0.797. This positive momentum is apparent with a trading volume of 7.90 million shares, indicating a surge in investor interest. Observers note that the stock may encounter resistance around $0.82 while support levels remain at $0.80, suggesting potential volatility in the short term which could present opportunities for active traders.
In conjunction with its market performance, Tiziana Life Sciences has announced a critical strategic shift concerning its innovative therapies. The biotechnology company is pivoting its focus following the identification of novel immune biomarkers in patients diagnosed with non-active secondary progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab. As part of its commitment to enhancing shareholder value, the management team has decided to pause any immediate capital raising activities. This decision aligns with Tiziana’s objective to further advance its pioneering drug candidates through ongoing clinical trials and regulatory review processes.
The development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody delivered via a proprietary nasal technology, positions Tiziana at the forefront of immunotherapy innovations. This method has the potential to improve both the efficacy and safety profiles of treatment, contrasting with conventional intravenous administration methods. Given its focus on alternative drug delivery modalities, Tiziana Life Sciences is well-equipped to explore diverse applications across its therapeutic pipeline, reinforcing its vital role in the evolving landscape of immunomodulation.
Related news for (TLSA)
- MoBot’s Stock Market Highlights – 07/30/25 04:00 PM
- 24/7 Market News Snapshot 23 May, 2025 – Tiziana Life Sciences Ltd. Common Shares (NASDAQ:TLSA)
- Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
- Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer’s Patient Treated with Intranasal Foralumab
- Breaking News: MoBot’s Latest Update as of 05/06/25 02:00 PM
